Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering Repeated Doses of ALECSAT to Prostate Cancer Patients.

NCT01422850 is registered in ClinicalTrials.gov with CytoVac A/S as lead sponsor.

NCT NCT01422850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01422850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering Repeated Doses of ALECSAT to Prostate Cancer Patients.
Lead sponsor
CytoVac A/S
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2011
Completion date
October 31, 2012
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-refractory prostate cancer